Background/Objectives: Although outcomes in Hodgkin lymphoma (HL) have improved substantially, patients with advanced-stage disease, comorbidities, or relapsed/refractory presentations can still fare poorly. Blood-based indices of systemic inflammation and nutrition are derived from routine tests, but their value beyond established prognostic models is uncertain. We examined the association of the baseline Gustave Roussy Immune Score (GRIm) and Glasgow Prognostic Score (GPS) with treatment response, progression-free survival (PFS), and overall survival (OS) in HL, focusing on their performance relative to the seven-factor International Prognostic Score (IPS-7). Methods: We retrospectively analysed 110 adults with histologically confirmed HL treated at a tertiary haematology centre between January 2015 and December 2025. GPS, GRIm, and IPS-7 were calculated from data recorded at diagnosis. Treatment response was classified as complete versus non-complete. Outcomes were assessed with Kaplan–Meier analysis, log-rank tests, Cox regression, Harrell’s C-index, and likelihood-ratio testing. Results: Most patients had advanced-stage disease (69.1%) and received ABVD-based treatment (94.5%); complete response was achieved in 90 (81.8%). GPS and GRIm were not significantly associated with non-complete response, whereas IPS-7 was. Over a median follow-up of 39.5 months, 28 patients (25.5%) progressed or died and 17 (15.5%) died. In univariable Cox analysis, high GRIm risk (HR = 2.68, 95% CI 1.17–6.14), higher GPS (HR = 2.18 per point, 95% CI 1.23–3.89), and higher IPS-7 (HR = 2.10 per point, 95% CI 1.59–2.77) predicted shorter PFS. For OS, GPS and IPS-7 were significant, whereas GRIm was not. After adjustment for IPS-7, neither GPS nor GRIm remained independently associated with PFS or OS, and adding either score to IPS-7 produced only small, non-significant gains in discrimination. Conclusions: Baseline GPS and GRIm were associated with survival on univariable analysis, particularly for PFS, but their incremental value beyond IPS-7 was limited. These scores may help describe baseline inflammatory and nutritional risk and should not be regarded as alternatives to established HL prognostic models. In particular, GPS and GRIm were not significantly associated with treatment response and should be viewed as supportive markers requiring external validation, rather than as tools that can independently guide treatment decisions.

Çalışmamızda esansiyel trombositemi (ET) tanılı hastalarda klinik, laboratuvar bulguları, tedavileri ile kanama ve tromboz durumlarını etkileyen faktörleri araştırmayı amaçladık. 2016- 2022 arası ET tanısı alan 270 hasta retrospektif incelendi, yaş ortalaması median 59 (19-92), %64’ü kadındı. Yüksek risk skoruna sahip olan JAK2 mutasyon pozitifliği %59 olup hastaların %39’ unda tromboz geliştiği (p=0.001), %23’ ünde kanama olduğu (p=0.008) saptandı. Ayrıca JAK2 pozitif olan hastaların çoğunun 60 yaş üstü olduğu (p=0.05), daha yüksek oranda miyelofibrozis geliştiği (p=0.007) görüldü. JAK2 mutasyonu pozitif hastaların, tanıda daha yüksek trombosit ve hemoglobin (Hb) değerine sahip olduğu bulundu (p=0.05, p=0.013). Hastalarımızın %33’ünde tanıda tromboz vardı (%89 arteryel ve %11 venöz trombozdu). Trombozu etkileyen risk durumları incelendiğinde; lökositoz, yüksek nötrofil ve Hb değeri ile istatistiksel anlamlılık saptandı (p=0.037, p=0.030, p=0.039). Multivariete analiz yapıldığında ise tromboz ile jak-2 pozitifliği ve lökositozun olması anlamlılığını koruyordu (p=0.022, p=0.006). Hastalarımızdan 217’si sağdı (%80). 10 yıllık sağkalım %75 olup, 60 yaş üstü hastalarda (p=0.001) ve tromboz olan hasta grubunda toplam sağkalım (OS) daha kısaydı (p=0.026). ELN risk skoru yüksek bulunan hastalarda sağkalım istatistiksel olarak anlamlı şekilde düşük saptandı (p=0.001) Revise-İPSET’ e göre orta ve yüksek skora sahip olanlarda sağkalım istatistiksel olarak anlamlı şekilde daha kısa bulundu (p=0.006). ET senelerce asemptomatik seyir gösterebileceği gibi, hayatı tehdit edebilen tromboembolik komplikasyonlar ve hemorajik durumlar ile karşımıza çıkmaktadır. Bu nedenle ET hastalarının yönetimi ve tedavi ihtiyacı olan yüksek riske sahip grubu tespit etmek önem taşımaktadır.

Aim: Despite high remission rates achieved with induction therapy in adult acute lymphoblastic leukemia (ALL), long-term survival outcomes remain unsatisfactory. This study aimed to explore the prognostic value of bone marrow fibrosis, bone marrow blast percentage, and selected serum biomarkers—albumin, beta-2 microglobulin (B2M), and lactate dehydrogenase (LDH)—at diagnosis in adult ALL patients. Materials and Methods: We retrospectively evaluated 116 adults diagnosed and treated for ALL between January 2006 and December 2018 in a single tertiary hematology center. Demographic, clinical, laboratory, genetic, and pathological characteristics were reviewed. The degree of bone marrow fibrosis was scored from 0 to 4. Survival outcomes were analyzed using Kaplan–Meier and Cox regression models. Results: The mean patient age was 43.1 years. Complete remission following induction was achieved in 83.6% of cases, and 40 patients underwent allogeneic stem cell transplantation. The median overall survival was 41.4 months, with an overall survival rate of 52.6%. No significant prognostic correlation was observed for serum LDH, B2M, albumin levels, or blast percentage at diagnosis. Conversely, advanced bone marrow fibrosis (grade 2–4) was significantly linked with inferior survival (p=0.024). Conclusion: Bone marrow fibrosis at presentation may serve as an independent predictor of poor prognosis in adult ALL, while the evaluated biomarkers and blast percentage were not prognostically informative. Integrating fibrosis assessment into clinical risk models could improve individualized treatment strategies and long-term outcomes.